Rising Breast Cancer Rates in Older Argentinian Women Demand Personalized Treatment Approaches
Argentina is facing a growing challenge: a significant rise in breast cancer diagnoses among women over 70, driven by increased life expectancy and an aging population. Approximately 22,000 new cases are diagnosed annually, with a third occurring in women over 70, highlighting the urgent need for tailored treatment strategies that consider both the disease and the patient’s overall health.
The Demographic Shift and Increasing Incidence
Population aging and increased longevity are primary factors contributing to the surge in breast cancer cases in older Argentinian women. Data from the Ministry of Health and the National Cancer Institute (INC) indicates that breast cancer accounts for 16.2% of all new cancer cases in the country. While the majority of these cancers are detected in their early stages – characterized by small tumors without lymph node involvement – the incidence notably increases after age 50, peaking between 70 and 74 (292.3 cases per 100,000 women) before declining slightly after age 85.
“Breast cancer in women over 70 years of age represents more than a third of new annual diagnoses,” explained breast cancer specialist Azul Perazzolo of the Alexander Fleming Institute Breast Center (IAF). “This trend responds to population aging and the increase in life expectancy, which allows more women to develop the disease.”
Biological Factors and Tumor Subtypes
Beyond demographic shifts, biological factors also play a role. Specialists note that older women accumulate greater exposure to both endogenous and exogenous estrogens, coupled with a reduced capacity for DNA repair. This combination increases the risk of oncogenic mutations and the development of various cancers, including breast cancer.
Breast tumors are broadly classified into three subtypes: luminal (estrogen and progesterone receptor positive), HER2 positive (expressing the HER-2 protein), and triple negative (lacking expression of all three receptors). “In people over 70 years of age, the probability of diagnosing luminal tumors is greater, which makes hormonal treatment especially relevant,” noted oncologist Laura Lapuchesky, also of the IAF Breast Center.
Balancing Treatment and Comorbidities: The Role of Oncogeriatrics
While breast cancer mortality rates in Argentina have decreased by 1% annually between 2002 and 2022, the absolute number of deaths remains high at 5,750 per year, with an adjusted mortality rate of 15.8 per 100,000 women. The risk of dying from breast cancer increases with age, reaching its peak in women over 80.
However, experts emphasize that breast cancer itself isn’t necessarily more dangerous with age. The critical factor is the increased prevalence of comorbidities – other health conditions – in older patients. “Per se breast cancer is no more dangerous after age 70, but it is an age group that presents greater comorbidities,” Dr. Perazzolo highlighted.
To address this complexity, the intervention of an oncogeriatrician is crucial. The IAF utilizes oncogeriatricians to detect “hidden fragility” in patients through a comprehensive gerontological evaluation. This evaluation assesses a patient’s functional age – their real physiological state influenced by lifestyle, environment, and genetics – which may differ significantly from their chronological age. The goal is to recommend treatments that prioritize maintaining, or even improving, a patient’s quality of life.
Debunking Myths and Promoting Early Detection
On World Breast Cancer Day, the medical community aims to dispel misconceptions surrounding the disease, particularly in older adults. A common myth is that tumors grow more slowly in patients over 70, leading to a dangerous tendency to underestimate the illness.
“The biological subtypes of breast cancer that are most frequently diagnosed in elderly patients tend to be slower growing,” explained Dr. Veronica Fabiano of the Alexander Fleming Institute. “However, early diagnosis and timely initiation of treatment continue to be essential to achieve the highest cure rates.”
Many older patients also have existing health conditions and take multiple medications, which can create reluctance towards aggressive oncological treatments. In these cases, a comprehensive evaluation by a multidisciplinary team, with a central role for the oncogeriatrician, is paramount. The objective is to avoid both overtreatment – therapies with limited benefit – and undertreatment – omitting potentially helpful options based solely on age. A personalized, ethical, and balanced approach is key.
Prevention, Screening, and Evolving Treatment Strategies
Prevention and early detection remain fundamental, tailored to the patient’s age and life stage. While breast self-examination is no longer routinely recommended, immediate medical consultation for any suspicious changes – a lump, discharge, or skin alterations – is vital. Risk assessment begins to increase around age 40, with annual mammograms advised by most medical societies. For women with dense breasts, ultrasound can enhance mammogram sensitivity, and MRI may be added for those at high risk due to genetic mutations or family history.
The prognosis for early-stage breast cancer remains excellent, with 5-year survival rates of 100% for stage 0, 99% for stage I, and 90-99% for stage II. Treatment is constantly evolving, encompassing surgery, radiotherapy, chemotherapy, and targeted therapies. For women over 70, minimally invasive strategies are particularly important, accounting for comorbidities while maintaining oncological efficacy.
“For example, chemotherapy regimens may be adapted to be better tolerated, or surgical techniques may be more conservative, especially in relation to the removal of axillary lymph nodes,” said mastologist and gynecologist Luciana Sabatini of the IAF. “The main challenge is to find an adequate balance between a good oncological result and a minimally invasive treatment that does not interfere with other comorbidities and preserves the quality of life of our patients.”
While there is no age limit for cancer treatment, its indication in elderly patients often decreases due to concerns about toxicity. Individual geriatric evaluation and attention to all comorbidities are therefore essential. Researchers are currently validating simple tools to estimate the risk of serious toxicity from oncological treatments in older patients.
Ultimately, promoting early detection and consistent monitoring throughout life is crucial. Prevention remains a lifelong endeavor, and early detection remains curable regardless of a patient’s age. “In clinical practice, many elderly women are left out of screening programs for various reasons,” concluded Dr. Perazzolo. “It is essential to personalize screening strategies, considering life expectancy, functional status and patient preferences.”
The Alexander Fleming Institute specializes in the prevention, diagnosis, treatment and monitoring of oncological diseases and medical innovation.
Keep reading
- Predicting Pathogen Risks in Drinking Water with Machine Learning (newsy-today.com)
